News

The decision comes after success during formulation testing with convincing stability data.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the pharma industry.

The facility, company says, will be its first that covers end-to-end ADC production.

The company increases its selection of atopic dermatitis treatments in the process.

Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.

Chip Davis recaps the organization’s Distribution Management Conference and addresses distributors’ preparedness for DSCSA implementation.

The company has financially committed $13.1 million into the project.

The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.

The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.

The development project adds an additional 157,500 square feet to the existing facility in the process.

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Cathy O'Brien, VP of Sales, UPS Healthcare discusses current technology that the pharma industry is adopting when it comes to sustainability.

Parties sign co-exclusive licensing agreement, which includes a minority equity investment in Novavax, who will be receiving payments totaling as high as $1.2 billion when combining upfront payment and milestones.

The network now includes 30 pharmacies, who will help tackle accessibility.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Cathy O'Brien, VP of Sales, UPS Healthcare discusses her masterclass on delivering agility in supply chains by building a multimodal cold chain network while also reducing risks at LogiPharma Europe 2024.

The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

Company's annual Commercial Summit updates Veeva Vault CRM status, along with AI partnerships.

The latest accreditation further establishes the company’s reputation in the pharma and healthcare logistics space.

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Martin Hawes, Global Head of Product Development, Tower Cold Chain offers insights on the future of cell & gene therapies when it comes to cold chain storage.

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

The partnership revolves around augmenting regulatory compliance, along with drug sampling distribution and compliance.

The CRO earned a Bronze rating for criteria based on environmental, social, and ethical performance.